ABPRO Holdings Inc (ABPO)

ABPRO Holdings Inc is a biotechnology company listed on OTC Markets under the ticker ABPO. The company focuses on developing novel antibody constructs for applications in immuno-oncology and ophthalmology. Its technology platforms include DiversImmune, which is designed to identify a broad set of proprietary antibodies against both established and emerging targets, and MultiMab, an engineering platform used to assemble antibody building blocks into full-length multi-specific constructs with different formats and orientations.

ABPRO’s development pipeline includes ABP-102, a TetraBi antibody intended to target HER2 and CD3 for HER2-positive solid tumors such as breast and gastric cancers, and ABP-201, which is being developed to inhibit VEGF and ANG-2 for eye diseases including diabetic macular edema and wet age-related macular degeneration. Additional programs include ABP-110 for hepatocellular carcinoma and ABP-150 for gastric cancers. The company also has strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc. ABPRO Holdings was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.